Avedro Holds Iontophoresis License

Avedro will hold the exclusive license to EyeGate Pharma’s iontophoresis patents in the field of corneal collagen cross-linking, according to a press release. When cross-linking is used to treat degenerative keratoconus or post-LASIK ectasia, the corneal epithelium is commonly removed to allow riboflavin to penetrate into the cornea. Removal of the epithelium causes patient discomfort for up to 24 hours and a transient reduction in vision as the epithelium regrows. Iontophoresis can potentially deliver riboflavin into the cornea without the need to remove the epithelium. Read more.